Sonnet biotherapeutics inc. enters into licensing agreement with alkem laboratories limited to develop and commercialize son-080 for diabetic peripheral neuropathy (dpn) in india

Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the india market

SONN Ratings Summary

SONN Quant Ranking